{"id":34056,"date":"2025-11-28T17:05:00","date_gmt":"2025-11-28T11:35:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=34056"},"modified":"2025-11-25T15:05:45","modified_gmt":"2025-11-25T09:35:45","slug":"redemplo-for-fcs","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/redemplo-for-fcs","title":{"rendered":"Arrowhead Hits the Mark in FCS Treatment with REDEMPLO Approval\u2014Now Comes the Ionis Challenge"},"content":{"rendered":"\n

Arrowhead Pharmaceuticals<\/strong> has reached a transformational milestone with the FDA\u2019s approval of REDEMPLO (plozasiran) <\/strong>on November 18, 2025\u2014marking the company\u2019s first FDA-approved medicine and the first-ever FDA-approved siRNA therapeutic for familial chylomicronemia syndrome (FCS) treatment. This historic approval represents not only a pivotal achievement for Arrowhead but also a breakthrough for the estimated 6,500<\/strong> Americans living with this severe and rare genetic metabolic disorder.<\/p>\n\n\n\n

Familial chylomicronemia syndrome is a devastating, rare disease characterized by triglyceride levels that reach 10 to 100 times higher than normal, typically exceeding 880 mg\/dL. According to DelveInsight\u2019s analysis, the US reported approximately 1,400<\/strong> diagnosed prevalent cases of FCS<\/a> in 2023, a figure projected to rise significantly from 2025 to 2034.\u00a0REDEMPLO uses an innovative approach that leverages small interfering RNA (siRNA) technology to target and suppress apolipoprotein C-III production. This liver-produced protein raises triglyceride levels by slowing their breakdown and clearance. By inducing sustained silencing of this target protein, REDEMPLO delivers significant and durable reductions in triglyceride levels\u2014addressing the root cause of the disease rather than merely treating symptoms.\u200b<\/p>\n\n\n\n

The therapeutic leverages Arrowhead\u2019s proprietary Targeted RNAi Molecule (TRiM) platform<\/strong>, which represents a differentiated approach to RNA interference therapy<\/a>. This platform is particularly notable because it has demonstrated the potential to deliver siRNA to seven different cell types in the body and can silence the expression of two genes with a single molecule, expanding the range of diseases Arrowhead may be able to address.<\/p>\n\n\n\n

The FDA recognized REDEMPLO\u2019s significance by granting the therapy Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation<\/strong> for FCS treatment. Additionally, the European Medicines Agency has granted Orphan Medicinal Product Designation, positioning the drug for potential international expansion.<\/p>\n\n\n\n

REDEMPLO\u2019s FDA approval is grounded in compelling efficacy data from the Phase 3 PALISADE study<\/strong>, a randomized, double-blind, placebo-controlled trial conducted across 39 sites in 18 countries with 75 subjects. The study met its primary endpoint and all multiplicity-controlled key secondary endpoints, demonstrating the drug’s remarkable effectiveness.\u200b<\/p>\n\n\n\n

The results were striking: patients receiving the 25-mg dose of REDEMPLO achieved a median reduction in triglycerides of 80% from baseline, compared to just 17% in the pooled placebo group. Beyond triglyceride reduction, the drug also significantly lowered apolipoprotein C-III (APOC3) levels, a key regulator of triglyceride metabolism. Perhaps most importantly for patients facing the constant threat of pancreatitis, the treatment group had a lower incidence of acute pancreatitis than the placebo.\u200b<\/p>\n\n\n\n

\"REDEMPLO-Development-Timeline\"<\/a><\/figure>\n\n\n\n

These data were simultaneously published in prestigious medical journals, The New England Journal of Medicine and Circulation<\/strong>, following presentations at the 2024 European Society of Cardiology Congress <\/strong>and the American Heart Association Scientific Sessions<\/strong>, lending significant credibility to the findings.<\/p>\n\n\n\n

The safety data from PALISADE demonstrate that REDEMPLO is generally well-tolerated. The most common adverse reactions (occurring in \u226510% of patients and >5% more frequently than placebo) are hyperglycemia, headache, nausea, and injection site reactions. Notably, the FDA-approved package insert lists no contraindications, warnings, or precautions for REDEMPLO use, reflecting a favorable safety profile.<\/p>\n\n\n\n

A major advantage of REDEMPLO is its convenient subcutaneous injection, administered once every three months at home, eliminating the need for frequent medical visits and improving FCS treatment adherence<\/a>. This patient-friendly administration schedule represents a significant improvement in quality of life for individuals managing a chronic disease with complex treatment requirements.<\/p>\n\n\n\n

Arrowhead has set REDEMPLO\u2019s annual price at $60,000<\/strong>, and executives have committed to a pricing model that sets a single price across current and future indications. This pricing strategy reflects the company’s commitment to value while ensuring sustainable commercialization of this rare disease therapy. To further improve patient access, Arrowhead is launching \u201cRely On REDEMPLO,\u201d<\/strong> a comprehensive patient support program that provides services, resources, and financial assistance to eligible patients.<\/p>\n\n\n\n

REDEMPLO enters a market that\u2019s no longer untested, thanks to the US approval last year of Ionis\u2019 RNA-targeted ligand-conjugated antisense therapy TRYNGOLZA (olezarsen)<\/strong>, the first FCS medicine specifically cleared in the country.<\/p>\n\n\n\n

The launch of Tryngolza also represents a milestone for Ionis: after more than 35 years in business, it is the first time the company has commercialized one of its own approved drugs rather than licensing it to a partner. Ionis reported $32 million<\/strong> in TRYNGOLZA sales for the third quarter and expects full-year 2025 revenues of $85\u201395 million<\/strong>.<\/p>\n\n\n\n

Even ahead of REDEMPLO\u2019s approval, Arrowhead and Ionis were already locked in a legal battle. In September, both companies filed competing lawsuits. Ionis claimed Arrowhead had copied its patented mRNA technology to develop REDEMPLO and sought unspecified damages in a California court. Arrowhead countered that the disputed Ionis patent is \u201cinvalid and not infringed\u201d by its planned commercialization of REDEMPLO. Both companies\u2019 FCS therapies<\/a> target the same pathway: reducing APOC-3 protein production.<\/p>\n\n\n\n

The REDEMPLO approval for FCS treatment comes at a particularly significant moment for Arrowhead, following a challenging period related to the company\u2019s partnership with gene therapy maker Sarepta Therapeutics<\/strong>. Last November, Arrowhead licensed multiple clinical and preclinical siRNA programs to Sarepta in a landmark $825 million<\/strong> upfront deal with potential additional payments reaching $10 billion<\/strong> based on clinical milestones. <\/p>\n\n\n\n

However, when Sarepta announced a safety-related strategic restructuring involving its gene therapy ELEVIDYS<\/strong><\/a> <\/strong>during the summer of 2025, Arrowhead\u2019s stock declined 12%<\/strong> over approximately one month as investors questioned Sarepta\u2019s execution capabilities. REDEMPLO\u2019s FDA approval, combined with increasing stability in the Sarepta partnership, represents a significant turning point for Arrowhead’s stock and investor confidence. <\/p>\n\n\n\n

\u201cWith its first FDA approval in the books, and some stability on the Sarepta front with an updated label for ELEVIDYS, the winds appear to be blowing in the right direction for Arrowhead.\u201d<\/em><\/p>\n\n\n\n

While REDEMPLO\u2019s approval for FCS treatment represents a landmark achievement, the drug\u2019s clinical development extends beyond this rare disease indication. Plozasiran is currently being investigated in the SHASTA-3, SHASTA-4, and SHASTA-5 Phase 3 studies<\/strong> for severe hypertriglyceridemia and the MUIR Phase 3 study<\/strong> for mixed hyperlipidemia. These ongoing REDEMPLO trials suggest that the drug\u2019s triglyceride-reducing capabilities may benefit a broader population of patients with less severe but more common lipid disorders.<\/p>\n\n\n\n

REDEMPLO is expected to be available in the United States before the end of 2025, providing long-awaited therapeutic hope to the FCS community. For Arrowhead Pharmaceuticals, this approval marks not just a commercial milestone but a validation of its scientific platform and commitment to developing innovative treatments for serious diseases. As the company transitions into commercial-stage operations with its first approved medicine, the success of REDEMPLO will be closely monitored by both the investment community and patients who desperately need effective treatments for rare metabolic disorders.<\/p>\n\n\n\n

\"Familial<\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"

Arrowhead Pharmaceuticals has reached a transformational milestone with the FDA\u2019s approval of REDEMPLO (plozasiran) on November 18, 2025\u2014marking the company\u2019s first FDA-approved medicine and the first-ever FDA-approved siRNA therapeutic for familial chylomicronemia syndrome (FCS) treatment. This historic approval represents not only a pivotal achievement for Arrowhead but also a breakthrough for the estimated 6,500 Americans […]<\/p>\n","protected":false},"author":14,"featured_media":34059,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[20821,15936,15935,15938,22777,22776,19938,22778],"industry":[17225],"therapeutic_areas":[17238],"class_list":["post-34056","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-elevidys","tag-familial-chylomicronemia-syndrome","tag-familial-chylomicronemia-syndrome-market","tag-familial-chylomicronemia-syndrome-pipeline","tag-plozasiran","tag-redemplo","tag-rna-interference","tag-tryngolza","industry-pharmaceutical","therapeutic_areas-genetic-disorders"],"acf":[],"yoast_head":"\nArrowhead Enters FCS Space with REDEMPLO Approval<\/title>\n<meta name=\"description\" content=\"On November 18, 2025, Arrowhead Pharmaceuticals has reached a transformational milestone with the FDA\u2019s approval of REDEMPLO (plozasiran).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/redemplo-for-fcs\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arrowhead Enters FCS Space with REDEMPLO Approval\" \/>\n<meta property=\"og:description\" content=\"On November 18, 2025, Arrowhead Pharmaceuticals has reached a transformational milestone with the FDA\u2019s approval of REDEMPLO (plozasiran).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/redemplo-for-fcs\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-28T11:35:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/25150310\/redemplo-for-fcs.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Arrowhead Enters FCS Space with REDEMPLO Approval","description":"On November 18, 2025, Arrowhead Pharmaceuticals has reached a transformational milestone with the FDA\u2019s approval of REDEMPLO (plozasiran).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/redemplo-for-fcs","og_locale":"en_US","og_type":"article","og_title":"Arrowhead Enters FCS Space with REDEMPLO Approval","og_description":"On November 18, 2025, Arrowhead Pharmaceuticals has reached a transformational milestone with the FDA\u2019s approval of REDEMPLO (plozasiran).","og_url":"https:\/\/www.delveinsight.com\/blog\/redemplo-for-fcs","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-11-28T11:35:00+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/25150310\/redemplo-for-fcs.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/redemplo-for-fcs","url":"https:\/\/www.delveinsight.com\/blog\/redemplo-for-fcs","name":"Arrowhead Enters FCS Space with REDEMPLO Approval","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/redemplo-for-fcs#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/redemplo-for-fcs#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/25150310\/redemplo-for-fcs.webp","datePublished":"2025-11-28T11:35:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"On November 18, 2025, Arrowhead Pharmaceuticals has reached a transformational milestone with the FDA\u2019s approval of REDEMPLO (plozasiran).","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/redemplo-for-fcs"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/redemplo-for-fcs#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/25150310\/redemplo-for-fcs.webp","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/25150310\/redemplo-for-fcs.webp","width":466,"height":284,"caption":"redemplo-for-fcs"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/25150310\/redemplo-for-fcs-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ELEVIDYS<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Familial Chylomicronemia Syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Familial Chylomicronemia Syndrome Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Familial Chylomicronemia Syndrome Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">plozasiran<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">REDEMPLO<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">RNA interference<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">TRYNGOLZA<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">ELEVIDYS<\/span>","<span class=\"advgb-post-tax-term\">Familial Chylomicronemia Syndrome<\/span>","<span class=\"advgb-post-tax-term\">Familial Chylomicronemia Syndrome Market<\/span>","<span class=\"advgb-post-tax-term\">Familial Chylomicronemia Syndrome Pipeline<\/span>","<span class=\"advgb-post-tax-term\">plozasiran<\/span>","<span class=\"advgb-post-tax-term\">REDEMPLO<\/span>","<span class=\"advgb-post-tax-term\">RNA interference<\/span>","<span class=\"advgb-post-tax-term\">TRYNGOLZA<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 months ago","modified":"Updated 5 months ago"},"absolute_dates":{"created":"Posted on Nov 28, 2025","modified":"Updated on Nov 25, 2025"},"absolute_dates_time":{"created":"Posted on Nov 28, 2025 5:05 pm","modified":"Updated on Nov 25, 2025 3:05 pm"},"featured_img_caption":"redemplo-for-fcs","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=34056"}],"version-history":[{"count":4,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34056\/revisions"}],"predecessor-version":[{"id":34064,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34056\/revisions\/34064"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/34059"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=34056"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=34056"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=34056"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=34056"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=34056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}